Key Takeaways

Semax is commonly described as a nootropic or neuroprotective peptide, but the most important scientific distinction is that it is a synthetic intranasal ACTH(4–10)-derived heptapeptide used in Russian medical practice, not an FDA-approved therapy in the United States.
Its canonical sequence is Met-Glu-His-Phe-Pro-Gly-Pro, and the official Russian product information describes labeled intranasal formulations and neurologic indications, but that does not establish U.S. approval, route equivalence, or broad clinical validation outside that regulatory context.
The studies below outline Semax's proposed roles in neurotrophic signaling, cognitive performance, ischemic-stroke recovery, and other neurologic or ophthalmic settings, but the accessible human evidence remains mostly small, Russia-centered, and not comparable to large, independently replicated modern clinical-trial programs.
Semax is therefore best framed as an investigational, evidence-limited neuroactive peptide outside approved Russian contexts, not as a proven treatment for focus, mood, memory, stroke recovery, ADHD, anxiety, anti-aging, or general brain optimization.

‍

[RLS, n.d.; Kaplan et al., 1996; Kurysheva et al., 2001; Ivanikov et al., 2002; FDA, 2026; Reuters, 2026].

‍

Semax: an unapproved synthetic neuroactive heptapeptide and adrenocorticotropic hormone fragment analogue, commonly described as an ACTH-derived peptide with canonical sequence Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP).

Overview

The core issue with Semax is not that there is zero science. It is that the available science is a mix of Russian product-history material, small or difficult-to-audit clinical-use claims, mechanistic and rodent papers, and current gray-market nootropic/peptide marketing. In practice, that evidence is often over-transferred across jurisdictions, routes, and product types. On July 24, 2026, the Pharmacy Compounding Advisory Committee voted 8-5, with one abstention, to recommend adding both Semax free base and Semax acetate to the 503A Bulks List; the recommendation is non-binding, and FDA has not yet taken final action. [FDA, 2026; NCATS, 2025; Reuters, 2026; The Guardian, 2026; Medsafe, 2025; Deigin et al., 2022]

What it is

Semax is a synthetic heptapeptide with canonical sequence Met-Glu-His-Phe-Pro-Gly-Pro. FDA's UNII system lists Semax under UNII I5FAL2585H, records the molecular formula as C37H51N9O10S, and notes synonyms that include "MET-GLU-HIS-PHE-PRO-GLY-PRO" and "ACTH (4-7), PRO-GLY-PRO-." NCATS Inxight Drugs likewise records Semax as a chemical substance with molecular weight 813.92 and "approval year" marked as unknown. [FDA, 2026; NCATS, 2025]

Semax is commonly described in the literature as a synthetic analogue developed from a fragment of adrenocorticotropic hormone, usually written as ACTH(4–10), with the resulting active peptide sequence rendered as MEHFPGP. The 2022 review on Russian peptide biopharmaceuticals describes Semax as a synthetic ACTH-fragment analogue developed in Russia, while FDA and NCATS identity systems confirm the discrete substance record for Semax. That means ACTH biology can provide context, but it cannot be collapsed into Semax efficacy claims. [Deigin et al., 2022; FDA, 2026; NCATS, 2025]

Russian source material describes Semax as a sterile intranasal solution in 0.1% concentration, later also discussed in 1% drops, whereas contemporary market channels also talk about Semax within the broader U.S. peptide economy that frequently normalizes injectable framing. Route, formulation, excipients, concentration, source quality, and jurisdiction all matter. Evidence belonging to a Russian drug product dossier or intranasal product history does not automatically belong to a compounded or gray-market peptide sold elsewhere. [Institute of Molecular Genetics, n.d.; CosmicNootropic, n.d.; Reuters, 2026; The Guardian, 2026]

Material	What it is
Parent ACTH	Endogenous pituitary hormone with broader hormonal biology. [Deigin et al., 2022]
Synthetic Semax substance record	Defined chemical identity with UNII I5FAL2585H and NCATS substance record. [FDA, 2026; NCATS, 2025]
Russian Semax nasal drops	Historically described intranasal pharmaceutical format product, including 0.1% sterile drops and later 1% product references. [Institute of Molecular Genetics, n.d.; CosmicNootropic, n.d.]
U.S. compounded / gray-market "Semax"	Contemporary peptide-market or nootropic-market offering, sometimes discussed within broader compounding and injectable peptide discourse. [Reuters, 2026; The Guardian, 2026]
Adamax	Distinct Semax-related analogue identified by Medsafe as an ACTH-analogue example marketed as a cognitive enhancer. [Medsafe, 2025]

How it's proposed to work

The best-supported mechanistic backbone comes from preclinical same-molecule work rather than from human therapeutic validation. In rats, Semax has been reported to increase hippocampal expression of brain-derived neurotrophic factor and TrkB, which is one reason it is repeatedly framed as a neurotrophic or neuroplasticity-adjacent peptide in the literature. [Dolotov et al., 2006; Deigin et al., 2022]

A second defensible mechanistic anchor is monoaminergic signaling. Eremin and colleagues reported effects of Semax on dopaminergic and serotoninergic systems in rodents, including activation patterns that are frequently used to explain nootropic, stimulant-adjacent, or mood-related claims. [Eremin et al., 2004; Eremin et al., 2005]

There is also a narrower biochemical strand around peptide-processing enzymes. Kost and colleagues reported that Semax and Selank inhibited enkephalin-degrading enzymes from human serum, with the article describing inhibitory activity in vitro. [Kost et al., 2001]

The most uncertain mechanistic branch is receptor-level shorthand. A 2012 review discussing drug-induced activation of nervous control of inflammation notes literature suggesting Semax may act through melanocortin receptors, including MC4 and MC5 receptor interactions. [Bertolini, 2012]

Common forms in circulation

The most clearly documented Semax product format is the Russian intranasal solution. The archived Institute of Molecular Genetics page describes a 0.1% sterile water solution in 3 mL bottles with droppers. It also describes later ophthalmic-related intranasal use in optic nerve disease contexts. The WHO-hosted archived Russian essential medicines entry supports Semax's presence in a Russian national vital and essential drugs framework tied to a December 7, 2011 government decree. [Institute of Molecular Genetics, n.d.; WHO, 2012]

Current nootropic retail listings that present themselves as carrying Russian-origin product continue to foreground intranasal drops, specifically 3 mL bottles in 0.1% and 1% strengths. [CosmicNootropic, n.d.]

The current peptide/nootropic market presents Semax as a cognitive-enhancement or "brain health" product, often emphasizing nasal drops, focus, stress resilience, and productivity. At the same time, contemporary reporting on FDA peptide policy places Semax inside a broader U.S. peptide economy that is frequently discussed in the language of injections, anti-aging, and telehealth peptide access. [CosmicNootropic, n.d.; Reuters, 2026; The Guardian, 2026; Medsafe, 2025]

Names and aliases

Key names and aliases to flag include Semax, SEMAX, Met-Glu-His-Phe-Pro-Gly-Pro, MEHFPGP, and ACTH (4-7), PRO-GLY-PRO-. [FDA, 2026; NCATS, 2025] Related but non-identical molecules or categories that should be kept separate include ACTH, ACTH analogues, Adamax, and Selank. Medsafe explicitly discusses Semax and Adamax under ACTH-analogue market activity, while current nootropic retail pages often contrast Semax with Selank or pair them conceptually. [Medsafe, 2025; CosmicNootropic, n.d.]

Regulatory status

No FDA-approved indication for Semax was verified. FDA's UNII Search Service lists Semax as a substance identity record and explicitly states that UNII availability does not imply regulatory review or approval. NCATS Inxight Drugs lists Semax with "Approval Year: Unknown." [FDA, 2026; NCATS, 2025]

FDA's May 2026 briefing document evaluated Semax free base and Semax acetate separately for cerebral ischemia, migraine, and trigeminal neuralgia. FDA staff had recommended against adding either substance to the 503A Bulks List, citing inadequate physicochemical characterization, unclear historical compounding use, insufficient effectiveness evidence, limited safety information, no human pharmacokinetic studies, no safety data for the proposed subcutaneous route, and unresolved immunogenicity and peptide-impurity concerns. [FDA Semax briefing document]

Internationally, Medsafe discusses ACTH analogues as a market category with nootropic claims, states that mechanism is often unknown, says there appears to be limited clinical research and little knowledge of side effects or long-term effects, and recommends that ACTH analogues including Semax and Adamax be captured as prescription medicines through a group entry in New Zealand. [Medsafe, 2025]

On July 24, 2026, the Pharmacy Compounding Advisory Committee met to reconsider Semax free base and acetate for potential inclusion on the 503A Bulks List, evaluating the substances for cerebral ischemia, migraine, and trigeminal neuralgia. The committee voted 8-5, with one abstention, to recommend adding both substances to the 503A Bulks List — against FDA staff's own recommendation. [FDA 7/23-24/26 PCAC; FDA Semax briefing document; Reuters 7/24/26]

The recommendation is advisory only: FDA has not added either substance to the 503A Bulks List, and the vote does not itself authorize compounding, establish safety or efficacy, or constitute FDA approval. Compounding review, advisory discussion, or market access through a compounding or gray-market channel is not the same thing as new-drug approval. [FDA, 2026; FDA 7/23-24/26 PCAC; Reuters, 2026]

Evidence base

Evidence tier	What qualifies	What it does not justify
Clinical trial	Prospective interventional human study of Semax itself, with clearly stated route, population, and outcomes.	Generalized claims that all Semax products, routes, and populations are effective or validated.
Animal model	In vivo rodent or other animal work using Semax with specified model and endpoint.	Human efficacy, human safety, route equivalence, or dosing generalization.
Mechanistic hypothesis	Cell, biochemical, receptor, pathway, transporter, or biomarker work.	Patient-facing therapeutic claims.
Anecdotal or commercial	Market pages, testimonials, influencer or biohacker discussion, stack logic, or clinic copy.	Scientific proof of benefit, safety, or legitimacy.

Purported benefits, by evidence

Purported benefit	What the evidence supports	What it doesn't support
Focus, attention, mental performance	Preclinical and review literature, plus historic product narratives, support that Semax has long been positioned as a nootropic/cognitive enhancer and studied for attention- and memory-related endpoints.	Does not support "clinically proven focus drug," "works for productivity," or modern U.S. patient-facing efficacy claims across formulations.
Neuroprotection / stroke recovery	Review literature and historic Russian use materials state Semax has been used in ischemic stroke and cerebrovascular contexts. FDA's 2026 review found only a meeting abstract for cerebral ischemia that lacked relevant clinical-endpoint detail and concluded that effectiveness was not established.	Does not support "treats stroke," "reduces stroke damage in humans," or "FDA-recognized stroke therapy."
Migraine / trigeminal neuralgia pain	One small, uncontrolled, open-label report evaluated adults with migraine, trigeminal neuralgia, or dental plexalgia. FDA concluded that the study had major design and endpoint limitations and did not establish effectiveness for migraine or trigeminal neuralgia.	Does not support "treats migraine," "relieves trigeminal neuralgia," or a validated analgesic indication.
Stress resilience / anxiolytic or antidepressant-like effects	Rat studies reported attenuation of chronic stress effects and changes in exploratory or emotional behavior.	Does not support "treats anxiety," "treats depression," or "balances mood" in patients.
BDNF / neuroplasticity support	Rat hippocampal work reported increased BDNF and TrkB expression.	Does not support "boosts BDNF in people," "rewires the brain," or "restores neurons."
Dopamine / serotonin support	Rodent neurochemical studies reported activation of dopaminergic and serotoninergic systems.	Does not support "clinically raises dopamine," "acts like a stimulant," or "improves motivation in humans."
Optic nerve / ophthalmic benefit	One Russian-language clinical report described Semax in glaucomatous optic neuropathy and the archived institute page describes optic-nerve use.	Does not support broad ophthalmic efficacy claims, U.S. standard-of-care language, or route generalization beyond the described context.
GI / ulcer support	A small publication reported peptic-ulcer therapy with Semax, which is enough to document that the claim exists in the literature.	Does not support "treats ulcers," GI-healing language, or current clinical recommendation.
ADHD / neurodevelopmental use	Historic Russian/product materials and later commentary have associated Semax with ADHD discussion.	Does not support "ADHD treatment," pediatric efficacy claims, or broad neurodevelopmental use.
Anti-aging / brain repair / performance hacking	Market behavior and broader peptide/nootropic discourse clearly place Semax in cognitive-enhancement and self-optimization channels.	Does not support "anti-aging treatment," "brain repair peptide," or "performance enhancer for athletes."

Key literature

Kost NV, Sokolov OI, Gabaeva MV, et al. Semax and selank inhibit the enkephalin-degrading enzymes from human serum. Bioorganicheskaia Khimiia. 2001;27(3):180-183. Enzyme inhibition hypothesis in vitro.

Eremin KO, Kudrin VS, Saransaari P, et al. Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochem Res. 2005;30(12):1493-1500. Same-molecule rodent CNS activity relevant to mechanistic framing.

Dolotov OV, Karpenko EA, Inozemtseva LS, et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res. 2006;1117(1):54-60. Rat hippocampal BDNF/TrkB expression findings.

Yatsenko KA, Glazova NY, Inozemtseva LS, et al. Heptapeptide semax attenuates the effects of chronic unpredictable stress in rats. Dokl Biol Sci. 2013;453:353-357. Chronic-stress model findings.

Deigin VI, Poluektova EA, Beniashvili AG, Kozin SA, Poluektov YM. Development of Peptide Biopharmaceuticals in Russia. Pharmaceutics. 2022;14(4):716. Development history, Russian peptide context, high-level clinical-use framing.

References

U.S. Food and Drug Administration. UNII Search Service: SEMAX, UNII I5FAL2585H.
U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act. Updated May 14, 2026.
U.S. Food and Drug Administration. July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee — FDA Briefing Document for Semax-Related Bulk Drug Substances. May 11, 2026.
National Center for Advancing Translational Sciences. Inxight Drugs substance record: SEMAX, I5FAL2585H.
Reuters. FDA advisory panel recommends peptide Semax be added to pharmacy compounding list. July 24, 2026.
The Guardian. FDA to discuss easing restrictions on peptides despite safety concerns. June 26, 2026.
Medsafe. Classification of Unscheduled Peptides. Submission to the Medicines Classification Committee. June 2025.
World Health Organization Essential Medicines and Health Products Information Portal. Vital and Essential Drugs List, 2012 – Russian Federation.
Institute of Molecular Genetics, Russian Academy of Sciences. Semax – an effective stimulator of the nervous system. Archived historical product page.

Semax